title: Outcomes and predictors of improved survival after gamma knife radiosurgery for metastatic brain tumors originated from breast carcinoma.
abstract: Gamma knife radiosurgery (GKRS) has emerged as a possible treatment option for metastasis brain tumor (MBTs) originated from breast cancer. However, the intermediate or long-term outcome of GKRS on MBTs originated from breast carcinoma is not well defined. The outcome of GKRS on MBTs derived from breast carcinoma was reviewed in our institution's case series. We performed a retrospective review (2000-2013) of 50 patients with MBTs originated from breast cancer who received GKRS. Out of 50 patients, 11 patients had recurrent tumors after microsurgical resection and the other 39 patients received GKRS alone. The study population was followed clinically and radiographically after GKRS treatment. GKRS on MBTs metastasized from breast cancer showed significant variations in tumor growth control (decreased in 14 (31.9 %) patients, arrested growth in 17 (38.6 %) patients, and progressed tumor in 13 (29.5 %) patients). The overall median survival in this case series was 33 months. In our case series, overall survival rate after 5 years was 20 %, whereas progression-free survival rate after 5 years was 30 %. The prognostic factors for improving survival in the patients with MBTs from breast cancer were recursive partitioning analysis (RPA) class I (p = 0.014), age ≤65 years (p = 0.025), controlled primary tumor (p = 0.04), and single number of MBTs (p = 0.022). Recent follow-up revealed that GKRS offers good overall survival period in both new and recurrent patients with MBTs originated from breast carcinoma. Thus, GKRS is a therapeutic option for new and recurrent patients with MBTs derived from breast cancer.
authors.affiliation: Department of Neurosurgery, LSU Health-Shreveport, 1501 Kings Highway, Shreveport, LA, 71130-3932, USA.
authors.forename: Shyamal C
authors.initials: SC
authors.lastname: Bir
authors.forename: Papireddy
authors.initials: P
authors.lastname: Bollam
authors.forename: Anil
authors.initials: A
authors.lastname: Nanda
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000556:secondary* / Q000601:surgery*; D001943:Breast Neoplasms / Q000556:secondary*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000379:methods*; D011379:Prognosis; D016634:Radiosurgery / Q000379:methods*; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
references.citation: Cancer. 1979 Nov;44(5):1913-8
references.pmid: 498057
references.citation: Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):409-14
references.pmid: 20133072
references.citation: Am J Clin Oncol. 2007 Jun;30(3):310-4
references.pmid: 17551311
references.citation: J Neurooncol. 1993 Feb;15(2):165-74
references.pmid: 8509821
references.citation: Cancer. 1997 Nov 1;80(9):1746-54
references.pmid: 9351543
references.citation: Radiat Oncol. 2013 May 29;8:131
references.pmid: 23718256
references.citation: Cancer J. 2000 Mar-Apr;6(2):88-92
references.pmid: 11069225
references.citation: Radiat Oncol. 2011 May 15;6:48
references.pmid: 21575163
references.citation: Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1155-61
references.pmid: 10725626
references.citation: Neurosurgery. 2005 Nov;57(5 Suppl):S45-53; discusssion S1-4
references.pmid: 16237288
references.citation: J Neurosurg. 2005 Aug;103(2):218-23
references.pmid: 16175849
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26
references.pmid: 12062592
references.citation: Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e739-47
references.pmid: 22024205
references.citation: J Neurosurg. 2006 Aug;105(2):213-9
references.pmid: 17219825
references.citation: Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v
references.pmid: 21109143
references.citation: Breast Cancer Res. 2008;10(1):R20
references.pmid: 18307763
references.citation: Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1132-40
references.pmid: 19345514
references.citation: Cancer. 2004 Apr 15;100(8):1705-11
references.pmid: 15073860
references.citation: Neurosurgery. 2010 Dec;67(6):1515-22
references.pmid: 21107182
references.citation: Ann Surg Oncol. 1997 Sep;4(6):481-90
references.pmid: 9309337
references.citation: Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):426-34
references.pmid: 11567817
references.citation: Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326
references.pmid: 12762877
references.citation: Neuroimaging Clin N Am. 2003 May;13(2):237-50, x-xi
references.pmid: 13677804
references.citation: Ann Surg Oncol. 2000 Jun;7(5):333-8
references.pmid: 10864339
references.citation: J Neurosurg. 2011 Mar;114(3):792-800
references.pmid: 20887087
references.citation: Cancer. 2007 Sep 1;110(5):973-9
references.pmid: 17647245
references.citation: Stereotact Funct Neurosurg. 1993;61 Suppl 1:45-50
references.pmid: 8115755
references.citation: J Korean Neurosurg Soc. 2011 Sep;50(3):179-84
references.pmid: 22102945
references.citation: Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
references.pmid: 10098435
references.citation: Acta Neurochir (Wien). 2003 Sep;145(9):755-60
references.pmid: 14505101
references.citation: J Neurosurg. 2009 Sep;111(3):439-48
references.pmid: 19301968
references.citation: Neurosurg Clin N Am. 1999 Apr;10(2):337-50
references.pmid: 10099098
references.citation: Sov Med. 1986;(10):93-5
references.pmid: 3810288
references.citation: Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):650-5
references.pmid: 22795806
references.citation: Neurosurg Focus. 2000 Aug 15;9(2):e2
references.pmid: 16836288
references.citation: CNS Drugs. 2013 Feb;27(2):121-34
references.pmid: 23239265
references.citation: J Neurosurg. 1999 Oct;91(4):563-8
references.pmid: 10507375